LOS ANGELES, Nov. 7, 2012 /PRNewswire/ -- BG Medical Technologies, Inc. (OTC: RIGH) CEO Angel Stanz is scheduled to speak on Friday, joining industry leaders at the aptly-timed National Marijuana Business Conference in Denver, Colorado. He appears alongside top industry professionals in technology, business operations, finance, law, and policy reform in discussing trends and forecasts for the medical cannabis industry. Mr. Stanz will focus specifically on Internet-related technologies and the profitable role they are expected to fill as the cannabis industry continues to expand.

"It is an absolute pleasure to be publicly speaking this week from the first state to fully repeal cannabis prohibition. Yesterday's election represents a historic moment that has further opened new frontiers in medical research, Internet applications, and data processing," stated CEO Angel Stanz. "The level of gravitas this moment represents for cannabis industry leaders is immeasurable. It strongly shines the spotlight on the benefits of regulated profit-earning models, stimulating local economies, and state revenues through taxation."

BG Medical Technologies reaffirms its 2013 plans to expand operations into Colorado and Washington State territories. BG Medical recognizes these locations as high-growth regions that will continue to foster development and influence across the national landscape.

About BG Medical Technologies

BG Medical Technologies develops technology and research software for the health industry with a focus on patient solutions for natural and herbal treatments, including medical cannabis. The Company collects data through a network of proprietary software, utilized by patients, retail operators, and medical professionals. The Company's current flagship product, BudGenius.com, is a social web platform designed to assist cannabis patients in selecting regionally available medicine that is paired to their needs. The Company operates an analytical chemistry laboratory designed for natural medicine study, utilized to determine potency and safety guidance for patients and medicine manufacturers.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.